Media headlines about Alexion Pharmaceuticals (NASDAQ:ALXN) have been trending somewhat positive on Friday, according to Alpha One Sentiment Analysis. The research firm, a subsidiary of Accern, rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Alexion Pharmaceuticals earned a coverage optimism score of 0.14 on Alpha One’s scale. Alpha One also assigned press coverage about the biopharmaceutical company an impact score of 95 out of 100, meaning that recent media coverage is extremely likely to have an impact on the stock’s share price in the next several days.
Here are some of the media headlines that may have effected AlphaOne Sentiment’s analysis:
- What to expect from biotech (finance.yahoo.com)
- Peek Under The Hood: IYH Has 11% Upside (nasdaq.com)
- Alexion Pharmaceuticals (ALXN) Receiving Somewhat Favorable Media Coverage, Analysis Finds (americanbankingnews.com)
- Alexion Pharmaceuticals, Inc. (ALXN) Upgraded to Hold by Zacks Investment Research (americanbankingnews.com)
- Alexion Pharmaceuticals (ALXN) Getting Somewhat Positive News Coverage, Analysis Shows (americanbankingnews.com)
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 118.72 on Friday. The stock has a market cap of $26.67 billion, a price-to-earnings ratio of 67.45 and a beta of 1.39. Alexion Pharmaceuticals has a 52 week low of $109.12 and a 52 week high of $162.00. The stock’s 50 day moving average is $121.51 and its 200 day moving average is $124.86.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, February 16th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.25 by $0.01. The business earned $831 million during the quarter, compared to the consensus estimate of $840.69 million. Alexion Pharmaceuticals had a return on equity of 10.58% and a net margin of 12.46%. The business’s revenue was up 18.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.13 EPS. On average, equities analysts forecast that Alexion Pharmaceuticals will post $5.23 EPS for the current year.
A number of analysts recently weighed in on the company. Oppenheimer Holdings Inc. restated a “hold” rating on shares of Alexion Pharmaceuticals in a report on Sunday, December 25th. Leerink Swann set a $211.00 price target on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, December 25th. Jefferies Group LLC set a $120.00 price target on Alexion Pharmaceuticals and gave the stock a “hold” rating in a report on Sunday, December 25th. Royal Bank of Canada set a $187.00 price target on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, January 21st. Finally, Robert W. Baird upgraded Alexion Pharmaceuticals to a “hold” rating in a report on Thursday, January 5th. Seven investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $167.74.
In related news, EVP Clare Carmichael sold 2,179 shares of Alexion Pharmaceuticals stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $131.66, for a total transaction of $286,887.14. Following the completion of the sale, the executive vice president now owns 33,980 shares in the company, valued at approximately $4,473,806.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Leonard Bell sold 8,725 shares of Alexion Pharmaceuticals stock in a transaction dated Tuesday, February 7th. The stock was sold at an average price of $125.97, for a total value of $1,099,088.25. Following the sale, the director now owns 395,979 shares of the company’s stock, valued at approximately $49,881,474.63. The disclosure for this sale can be found here. In the last quarter, insiders have sold 26,084 shares of company stock valued at $3,344,493. 4.41% of the stock is currently owned by company insiders.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.